| dc.contributor.author | Yerlioğlu, Dilay | |
| dc.date.accessioned | 2021-03-02T21:50:05Z | |
| dc.date.available | 2021-03-02T21:50:05Z | |
| dc.identifier.citation | Yerlioğlu D., "Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on Infliximab", ESPGHAN 52nd Annual Meeting, Glasgow, İskoçya, 5 - 09 Haziran 2019, ss.117 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_09243852-0e63-4053-9a64-ac328e40bac5 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/11961 | |
| dc.identifier.uri | https://www.espghancongress.org/fileadmin/user_upload/downloads/Scientific_Programme/ESPGHAN2019_Programme_Book.pdf | |
| dc.description.abstract | Treat to target strategy has been proposed in adult IBD to improve Quality of
Life, symptoms and to treat inflammation. There is little data in the paediatric population for this
approach. The aim of this study was to look if set goals (reduced PCDAI/PUCAI and Mayo/SESCD)
were achieved. | |
| dc.language.iso | eng | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.title | Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on Infliximab | |
| dc.type | Bildiri | |
| dc.contributor.department | İstanbul Üniversitesi , İstanbul Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü | |
| dc.contributor.firstauthorID | 2258214 | |
